Table of Contents

Blastomyces & Talaromyces marneffei

Module Learning Objectives

By the conclusion of this exhaustive master guide, you will be deeply conversant with:

The complete epidemiology, ecology, and transmission pathways of Blastomyces dermatitidis.
The precise morphological and microscopic identifying features of the organism in both its mycelial and yeast phases.
The complex pathophysiology, host defense evasion mechanisms (such as the WI-1 Antigen), and clinical manifestations of Blastomycosis across multiple organ systems.
The taxonomic shift, geographical restriction, and devastating clinical impact of Talaromyces marneffei in immunocompromised hosts.
The gold-standard diagnostic protocols, histopathological stains, and definitive pharmacological treatment regimens for both fungal infections.

Part I: Introduction to Blastomyces dermatitidis

Blastomyces dermatitidis is a highly virulent, thermally dimorphic fungus responsible for causing a profound systemic, pyogranulomatous disease known universally as Blastomycosis. Unlike opportunistic fungi that only target the weak, this organism is fully capable of causing severe disease in young, healthy, immunocompetent individuals.

General Characteristics & Disease Progression:

Primary Entry: The initial infection occurs almost exclusively through the lungs via the inhalation of aerosolized spores. This primary pulmonary stage is often entirely asymptomatic or manifests as a mild, self-limiting flu-like illness that escapes clinical detection.
Hematogenous Dissemination: If the immune system fails to contain the initial pulmonary focus, the fungus rapidly invades the bloodstream. This hematogenous spread is not uncommon and constitutes the most dangerous phase of the disease.
Major Organ Involvement: Clinical disease most often aggressively involves four major systems: the Lungs (pneumonia, ARDS), Skin (ulcerative/verrucous lesions), Bones (osteomyelitis), and the Genitourinary (GU) system (prostatitis, epididymo-orchitis).
Epidemiological Note (The "No Animal" Rule): Unlike Histoplasmosis (which is heavily associated with bats and birds/guano) or Coccidioidomycosis (desert rodents), there is absolutely no association with animals as a reservoir or vector for Blastomyces. The soil itself is the solitary reservoir.

Ecology & Epidemiology:

Geographic Distribution: It is highly endemic to specific global regions. In North America, it heavily shadows the Ohio and Mississippi River valleys, the Great Lakes region, and the St. Lawrence River. It is also found in Africa, Central America, South America, India, and the Middle East.
Habitat: It thrives in warm, moist, acidic soil containing heavily decayed vegetation and decomposed wood. (Extra Clinical Example: Outbreaks frequently occur among forestry workers, individuals dismantling old beaver dams, or people exploring rotting wooden structures in deep woods).
Risk Factors: Direct, physical exposure to the contaminated soil is the primary risk. Interestingly, there is no sex, age, race, occupational, or seasonal predilection for blastomycosis. It strikes opportunistically upon exposure, meaning a healthy 25-year-old female hiker is just as susceptible as a 60-year-old male farmer if they disturb the same patch of soil.

Part II: The Organism: Morphology & Physiology

Classification & Serotypes

The fungus has a complex life cycle, existing in both sexual and asexual forms depending on the environmental conditions.

Sexual Stage: Known taxonomically as Ajellomyces dermatitidis. It is heterothallic, meaning it strictly requires opposite mating types (+ and - strains) to come together for fertile sexual reproduction in the environment. Both mating types are proven to be equally pathogenic to humans.
Asexual Stage: Known as B. dermatitidis. This is the stage that exhibits the famous thermal dimorphism (changing shape based purely on temperature).
Serotypes: Two distinct serotypes are identified via advanced exoantigen analysis. The A antigen–deficient serotypes are exclusively restricted to the African continent, providing an epidemiological fingerprint.

Environmental Form

The Mycelial Phase (Mold at Room Temp - 25°C)

This is the infectious form found in the soil.

Macroscopic: Grows in the lab or nature as a fluffy white mold that slowly matures, turning a light brown or tan color over 1 to 3 weeks.
Microscopic: Features septate, branching hyphae (2 to 3 μm in diameter).
Conidiophores: These spore-bearing structures arise at perfect, distinct right angles to the main hyphae, producing single terminal conidia (spores) that are 2 to 10 μm, round or oval-shaped.
Infectivity: These microscopic conidia are highly infectious to humans. When the mycelia are physically disturbed (e.g., kicking dirt, digging, bulldozing), the conidia become aerosolized, float in the air, and are inhaled deeply into the human alveoli.

Pathogenic Form

The Yeast Phase (Parasitic at 37°C) - HIGH YIELD

This is the destructive form found inside the human body.

Mechanism of Dimorphism: The transition from mold to yeast is directly mediated by heat-related stress (human body temperature of 37°C) and the physiological uncoupling of oxidative phosphorylation, forcing the fungus to adapt its metabolism.
Macroscopic: In a 37°C incubator, yeast colonies appear deeply wrinkled, folded, and cream/tan in color.
Microscopic Features (Board Exam Buzzwords):
- Large cells: Massive compared to other fungi, measuring 5 to 30 μm in diameter.
- Multinucleate: Each individual yeast cell contains 8 to 12 distinct nuclei.
- Thick, highly refractile cell wall: Composed of dense chitin and glucans, it bends light so intensely that it looks like a distinct "double line" or "railroad track" under the microscope.
- Broad-Based Budding: It reproduces by forming single buds with a very wide, broad base (neck) between the parent and the bud. The daughter cell remains attached and grows to nearly the exact same size as the mother cell before it finally detaches.

Mnemonic

Microscopic Identification of Blastomyces

To instantly differentiate Blastomyces from other dimorphic fungi (like Histoplasma which has narrow-based budding, or Coccidioides which forms spherules) under the microscope, remember the 3 B's:

"Blasto Buds Broadly"

If a pathology report or exam vignette describes a thick-walled yeast with a bud connected by a wide, thick neck (a broad base), you are looking at Blastomyces dermatitidis. There is no other correct answer.

Part III: Pathogenesis and Pathology

Transmission Routes:

Lungs (The Primary Gateway): The major, almost exclusive portal of entry is via the inhalation of conidia. Disease appearing at any other body site (skin, bone, brain) is almost always the direct result of hematogenous dissemination (bloodstream spread) escaping from this primary lung focus.
Skin (Direct Inoculation): Primary cutaneous blastomycosis without lung involvement is incredibly rare. It only occurs via accidental, direct inoculation. (Extra Clinical Examples: A microbiologist accidentally stabbing their finger with a contaminated scalpel in the lab, a pathologist nicking themselves during an autopsy of an infected patient, or a bite from a hunting dog that has infected soil/fungus in its mouth).
Person-to-Person: Extremely rare and not widely documented in standard transmission models. There are only a few isolated, highly unusual medical case reports (e.g., sexual transmission causing vaginal infection from a man with severe GU blastomycosis, or perinatal transmission from an infected mother to a fetus during childbirth).

Pathophysiology of Infection:

Inhalation & Deposition: The microscopic inhaled conidia bypass the upper airway defenses and deposit deep in the terminal bronchioles and alveoli. (The infective dose is terrifyingly small: as little as one single arthroconidium can establish an infection!)
Thermal Conversion: To survive the harsh human immune environment and the 37°C temperature, the conidia rapidly convert to the massive, thick-walled yeast phase.
The Pyogranulomatous Response: Blastomyces causes a highly unique, dual-threat inflammatory response in the host tissue:
- Pyogenic (Acute Phase): It triggers massive influxes of neutrophils, creating suppurative, pus-forming microabscesses.
- Granulomatous (Chronic Phase): Simultaneously, it triggers macrophages and T-cells, leading to the formation of noncaseating granulomas packed with epithelioid cells and multinucleated giant cells attempting to wall off the massive yeast.
Cutaneous/Mucosal Pathology: When the fungus spreads to the skin, it causes a highly deceptive histological reaction known as pseudoepitheliomatous hyperplasia. This is a massive, downward overgrowth of the skin epidermis (hyperplasia) with intense microabscess formation.
Clinical Trap: Because the epidermal cells are growing so wildly to push the fungus out, it looks histologically and grossly identical to Squamous Cell Carcinoma (SCC) or a giant keratoacanthoma! Without a fungal stain, a surgeon might mistakenly diagnose cancer and unnecessarily amputate a limb.

Part IV: Host Defenses, Immunity & Virulence

Natural Immunity & The Role of PMNs

The high frequency of asymptomatic infections in endemic areas proves that healthy people possess robust natural resistance. However, the battle at the microscopic level is intense.

The Conidia vs. Yeast Battle:

Defeating the Conidia: If the fungus remains in the spore (conidia) form, it is highly vulnerable. Conidia are efficiently phagocytized and rapidly killed by Polymorphonuclear neutrophils (PMNs) via intense oxidative mechanisms (the respiratory burst). This killing is heavily enhanced by complement proteins and divalent cations. Furthermore, alveolar macrophages can inhibit the conidia from transforming into yeast.
The Yeast Evasion: If the conidia successfully convert to the yeast form, the tide of the battle turns. Yeast forms are massive (up to 30 μm) and possess a thick, chitinous, antiphagocytic wall. They physically cannot be easily swallowed by macrophages. More importantly, they completely evade the respiratory burst—they do not stimulate the release of myeloperoxidase-dependent microbicidal products. This evasion by the yeast is the primary factor allowing disease progression.

Virulence Factors of the Yeast:

The yeast form is a heavily armored, biochemically advanced pathogen.

Thick cell wall & High lipid concentration: Provides a physical armor that is strongly antiphagocytic.
WI-1 Antigen (120-kDa glycoprotein) - THE ULTIMATE WEAPON: This is a novel, incredibly powerful virulence factor plastered on the surface of the yeast cell.
- It serves as the major epitope (target) for both the host's humoral and cellular immunity.
- It functions as a highly specialized adhesin. It physically binds to host immune receptors (specifically CR3 & CD14 on human macrophages) and enables tight binding to the human extracellular matrix, anchoring the fungus in the tissue.
- Immune Sabotage: Once bound, the WI-1 antigen actively blocks the production of TNF-α (Tumor Necrosis Factor-alpha) by macrophages and neutrophils. By shutting down TNF-α, the fungus essentially cuts the "alarm wire," preventing the host from mounting a full inflammatory response.
- It directly inhibits complement activation, preventing the body from punching holes in the fungal membrane.

Adaptive Immunity:

Cellular Immunity (CMI): This is the major, most critical acquired host defense! Macrophages eventually recognize the WI-1 antigen and present it to T-cells. T-cell derived cytokines (especially IFN-γ / Interferon-gamma) are absolutely required to supercharge the macrophages, allowing them to finally kill the massive yeast cells.
Humoral immunity: Antibodies generated against WI-1 and Complement play a supporting role, but without a strong T-cell (CMI) response, the patient will succumb to the disease (which is why immunocompromised/HIV patients suffer severe disseminated forms).

Part V: Clinical Manifestations

Blastomycosis is a systemic, multi-organ disease. Because no single clinical syndrome is exclusively characteristic of it, it is referred to as "The Great Pretender" and is frequently misdiagnosed for months.

1. Pulmonary Disease

The most common manifestation, as the lungs are the portal of entry.

May present as acute pneumonia (high fever, chills, productive cough, pleuritic chest pain) or chronic indolent pneumonia (weight loss, night sweats, chronic cough).
The Mimic: It frequently perfectly mimics pyogenic bacterial pneumonias, Tuberculosis (TB), other fungal infections (like Histoplasmosis), or primary lung malignancy (lung cancer). (Extra Example: A patient with a chronic cough and a lung mass on an X-ray might be scheduled for a lung cancer resection, only for the biopsy to reveal Blastomyces yeast instead of a tumor).

2. Cutaneous Disease

The absolute most common extrapulmonary (outside the lung) manifestation.

Presents as highly distinctive verrucous (warty) or deeply ulcerated lesions with violently heaped-up, crusted borders. They frequently occur on exposed skin like the face, neck, and arms.
Differential Diagnosis (DDx): Because of its bizarre appearance, doctors must rule out Bromoderma, pyoderma gangrenosum, Majocchi’s granuloma, leishmaniasis, Mycobacterium marinum (fish tank granuloma), giant keratoacanthoma, and Squamous Cell Carcinoma (SCC).

3. Other Extrapulmonary Sites

Once in the blood, the yeast can seed almost every organ.

Bones & Joints: Osteomyelitis occurs in up to 25% of systemic cases. It causes severe, punched-out osteolytic lesions in the long bones, ribs, and vertebrae, causing severe bone pain and pathological fractures.
Genitourinary (GU) Tract: Highly specific to Blastomyces. It frequently seeds the prostate and epididymis in men, causing painful prostatitis or epididymo-orchitis.
Central Nervous System (CNS): Meningitis or brain abscesses can occur in severe disseminated disease (highest mortality rate).
Rare sites: Liver, spleen, GI tract, thyroid, pericardium, adrenal glands (causing adrenal insufficiency).

Part VI: Laboratory Diagnosis

Because the clinical signs mimic cancer and TB, absolute laboratory confirmation is mandatory before initiating heavy, toxic antifungal therapy.

1. Direct Examination & Microscopy:

Wet prep (without KOH): Very low diagnostic yield (only 36% positive for a single specimen).
Calcofluor white stain: A fluorescent stain that binds to the chitin in the fungal wall. Requires a specialized fluorescence microscope. It is easy, rapid, and highly useful when the organisms are very sparse in the tissue.
Cytology: Yields a 56% sensitivity overall (jumps to 72% for pulmonary cases using bronchial washings or bronchoalveolar lavage [BAL]). Highly useful when patients cannot produce sputum, or when ruling out lung malignancy.
Histopathology: Routine H&E (Hematoxylin and Eosin) stains visualize the fungus poorly because the cell wall does not take up the dye well. Special stains are absolutely required:
- GMS (Gomori methenamine-silver): Stains the fungal cell wall crisp black against a green background.
- PAS (Periodic acid–Schiff): Stains the fungus bright magenta/red.
- Mayer mucicarmine: Used to differentiate it from Cryptococcus.

2. Culture (The Definitive Diagnosis):

Growing the organism is the gold standard.

Yield: High diagnostic yield from fresh sputum (75-86%) and Bronchoscopic BAL specimens (92%).
Media: Sabouraud dextrose agar, Sabhi, Brain Heart Infusion (BHI) agar, Gorman's medium. Selective media must use antibiotics (chloramphenicol) & anti-mold agents (cycloheximide) to prevent fast-growing bacteria from overtaking the slow-growing fungus.
Growth: Must be grown aerobically at 30°C for 5 to 7 days (appears initially as a white mold).
Critical Confirmatory Step: The mycelial (mold) form is NOT diagnostic on its own, because it looks identical to dozens of other non-pathogenic environmental molds. To officially confirm B. dermatitidis, the lab must do one of two things:
1. Physically convert the mold to the yeast form by raising the incubator to 37°C.
2. Use a specific highly advanced DNA probe or exoantigen test directly on the mold!

3. Antigen & Nucleic Acid Detection:

Antigen Detection: Best performed on urine (70-80% sensitivity for disseminated disease, a flawless 100% for severe pulmonary). Specificity is >90%. Warning: The test heavily cross-reacts with Histoplasmosis antigen, so clinical context is required.
Nucleic Acid (PCR): The Gen-Probe nonisotopic kit detects specific fungal RNA in very young cultures, massively shortening identification time from weeks to mere hours! Nested/multiplex PCR specifically targets the rRNA gene and the virulence WI-1 adhesin gene.

4. Serology & Immunity Testing:

Blood antibody testing is highly flawed in Blastomycosis. False-positives and negatives are extremely common. A negative titer never rules out disease, and a positive titer alone doesn't guarantee an active disease requiring therapy.

Complement-Fixation (CF): Older test; neither specific nor sensitive. Largely abandoned.
Immunodiffusion (ID): Detects bands of precipitation. More sensitive (52-80%) and highly specific (no cross-reactivity with other fungi), but it takes weeks to turn positive, offering little help in acute, emergency disease.
ELISA / RIA: Rapid and highly sensitive, but specificity is poor (too many false positives).
Note: There is currently NO reliable skin test reagent (like the PPD for Tuberculosis) available for Blastomycosis.

Part VII: Treatment Guidelines

Therapy is dictated by the severity of the disease and whether it has invaded the Central Nervous System (CNS).

Type of Disease	Preferred First-Line Therapy	Alternative / Step-Down Therapy
Serious Pulmonary (Hypoxia, ARDS)	Amphotericin B (0.3 - 0.6 mg/kg/day IV)	Change to oral Itraconazole after the patient's condition clinically stabilizes.
Mild to Moderate Pulmonary	Itraconazole (200 - 400 mg/day orally)	Ketoconazole or Fluconazole (400-800 mg/day).
Disseminated with CNS Involvement (Meningitis)	Amphotericin B (High dose: 0.7 - 1.0 mg/kg/day IV). Must cross the blood-brain barrier.	If patient cannot tolerate the severe kidney toxicity of Ampho B, use extremely high-dose Fluconazole (800 mg/day).
Serious Non-CNS Disseminated (Bones, Skin, GU)	Amphotericin B (0.3 - 0.6 mg/kg/day IV)	Change to oral Itraconazole after stabilization.

Clinical Pharmacology Note: Fluconazole is generally NOT recommended as a first-line drug for Blastomycosis (outside of desperate CNS salvage therapy) because it has devastatingly high clinical failure rates (>60%), requires massive, liver-toxic doses, and patients frequently relapse. Itraconazole is the absolute azole of choice!

Newer, highly advanced therapies for refractory cases include Voriconazole, Posaconazole, Echinocandins (Caspofungin), and Nikkomycin Z.

❓ Applied Clinical Question: The Mimic

Case: A 45-year-old lumberjack from Wisconsin presents to the clinic with a chronic, hacking cough and a large, ulcerated, warty (verrucous) skin lesion on his right forearm. A biopsy of the skin lesion is sent to pathology. It shows massive pseudoepitheliomatous hyperplasia, leading the junior pathologist to initially diagnose Squamous Cell Carcinoma (skin cancer). However, a senior pathologist orders a GMS stain, which reveals large, 20 μm cells with thick walls and a single bud attached by a very wide neck.

What is the definitive diagnosis, and what is the primary virulence factor allowing this organism to evade the patient's neutrophils?

Answer: The definitive diagnosis is Cutaneous Blastomycosis (confirmed by the classic "broad-based budding" yeast on the GMS stain). The primary virulence factor responsible for the immune evasion is the WI-1 Glycoprotein Antigen. This advanced adhesin blocks TNF-α production and prevents macrophage/neutrophil activation, working alongside its massive, thick, antiphagocytic cell wall to survive the respiratory burst.

Part VIII: Talaromyces marneffei (Formerly Penicillium marneffei)

Talaromyces marneffei is a highly dangerous, opportunistic, thermally dimorphic fungus that causes life-threatening systemic, disseminated infections, almost exclusively striking immunocompromised hosts (specifically those with advanced HIV/AIDS).

Taxonomic Classification & Nomenclature:

Previously classified under the Penicillium genus (known for their brush-like conidiophores), advanced DNA sequencing and phylogenetic mapping resulted in its complete reclassification and new name: Talaromyces marneffei.

Kingdom: Fungi ➔ Phylum: Ascomycota ➔ Class: Eurotiomycetes ➔ Order: Eurotiales ➔ Family: Trichocomaceae ➔ Genus: Talaromyces.

Epidemiology & Historical Context:

Geography (Highly Restricted): Unlike Blastomycosis, which spans multiple continents, Talaromyces marneffei is strictly, endemically limited to Southeast Asia and Southern China (with Thailand, Vietnam, and Hong Kong being massive hotspots).
Historical Timeline: The first human infection was described in 1959 in a laboratory worker. By 1988, the first terrifying reports emerged in HIV-infected patients. By the 1990s, parallel with the explosion of the HIV pandemic, it became the 3rd most common HIV opportunistic infection in northern Thailand (with the annual incidence rising violently to 1300 cases in 1995 alone).
Reservoir: It naturally resides in the soil and is heavily associated with Bamboo Rats (Cannomys and Rhizomys species) acting as an animal reservoir.
Transmission: Infection occurs via the inhalation of aerosolized conidia from the environment. Epidemiological data shows it is significantly more common during the tropical rainy seasons, as rain physically disrupts the soil, aerosolizing the spores.
Major Risk Factor: HIV/AIDS (specifically a CD4 count <100 cells/μL). While it can affect young adults, children, and adults with or without HIV, untreated HIV universally causes rapid, fulminant (explosive), and deadly disease.

Part IX: Clinical Manifestations of Talaromycosis

Talaromycosis presents as a highly destructive chronic illness, typically progressing over a 4-week duration before patients seek desperate medical care.

Most Common Systemic Symptoms: Low-grade chronic fever, severe cachexia (weight loss), profound malaise, severe anemia, leukocytosis (high white blood cell count), and highly characteristic skin lesions.
Other Symptoms: Fungemia (fungus actively replicating in the blood), generalized diffuse lymphadenopathy (swollen lymph nodes), chronic cough, and massive hepatomegaly/splenomegaly (enlarged liver and spleen as the fungus attacks the reticuloendothelial system).

The HIV/AIDS Presentation

Classic Presentation in Advanced Immunosuppression:

Skin Lesions (The Hallmark): Appear aggressively on the face, upper trunk, and extremities. They classically present as papules, pustules, or nodules that rapidly become umbilicated (developing a central dimple or crater).
Clinical Trap: Because of this umbilication, they look macroscopically identical to the viral infection molluscum contagiosum or even cutaneous cryptococcosis!
Mucosal: Destructive pharyngeal and palatal ulcerative lesions in the mouth.
Lung Lesions: Chest X-rays show reticulonodular, nodular, or diffuse alveolar infiltrates, cavitations (holes in the lung), and patients frequently present with severe hemoptysis (coughing up bright red blood).
Massive Dissemination: Without a functional T-cell response, the fungus spreads unimpeded to the bone marrow, meninges (brain), tonsils, bowel lining, and kidneys, leading to rapid multi-organ failure.

Part X: Diagnosis & Treatment

Diagnosis Methods:

Direct Microscopy: Smears taken directly from skin lesions, lymph node aspirates, bone marrow biopsies, blood, BAL fluid, or sputum. Under the microscope, it shows distinct Yeast forms located both intra-cellularly (packed entirely within human macrophages) and extracellularly.
Morphology Note: Unlike the budding of Blastomyces, T. marneffei yeast divide by binary fission (planate division), showing a distinct central septum (a wall dividing the cell in half) rather than a bud.
Histology: Tissue biopsies show intense granulomatous, suppurative, and necrotizing inflammation.
Serology & Advanced Diagnostics: Rapid antibody & antigen tests, tissue immunolabelling, and modern PCR techniques targeting specific fungal DNA.

Culture (The Diagnostic Hallmark)

Culturing the organism on agar provides the most visually stunning and definitive diagnosis in microbiology.

At 30°C (Mold form): It produces a rapidly growing mold with sporulating structures. Most uniquely, it actively synthesizes and secretes a highly soluble bright RED pigment that diffuses deeply into the surrounding agar plate, staining it blood-red!
At 37°C (Yeast form): If the incubator temperature is raised, the red mold completely converts to the pale yeast form (absolutely proving thermal dimorphism and confirming pathogenicity).

Board Exam Hint: If a clinical vignette mentions an Asian patient, or a traveler returning from Thailand, with a history of HIV, presenting with molluscum-like umbilicated skin bumps, and a lab culture mold that turns the agar blood-red at room temperature = Talaromyces marneffei. There are no exceptions.

Treatment Protocols:

Because the disease is frequently fulminant and fatal in HIV patients, aggressive, two-phased antifungal therapy is mandatory.

Phase of Treatment	Recommended Antifungal Therapy
Induction (Disseminated/Severe Disease)	Amphotericin B IV (often combined with oral flucytosine) for 2 weeks to rapidly clear the blood and stabilize the patient.
Consolidation & Maintenance (Mild Disease)	Itraconazole (400 mg/day for 10 weeks, then 200 mg/day). In HIV patients, lifelong suppressive maintenance therapy is required until Antiretroviral Therapy (ART) restores their CD4 count above 100 cells/μL.
Prophylaxis (for severe HIV in endemic regions)	Itraconazole or Ketoconazole to prevent primary infection.

Crucial Warning: Avoid Fluconazole! Clinical trials have proven that Fluconazole has unacceptably high therapeutic failure rates (over 60% of patients will die or fail to improve). It must not be used for T. marneffei.

❓ Final Module Review Question

Case: A 35-year-old male with untreated, advanced HIV living in Chiang Mai, Thailand, presents to the emergency department with a 4-week history of spiking fevers, profound weight loss, and multiple umbilicated papules across his face, chest, and arms. A biopsy of a skin lesion is taken and cultured on Sabouraud agar at 25°C. After several days, the agar immediately surrounding the growing mold colonies turns a deep, diffusing red color.

What is the exact organism, and what is the preferred maintenance treatment once the patient is stabilized?

Answer: The organism is Talaromyces (Penicillium) marneffei. The geographical location (Thailand), the severe immunocompromised status (untreated HIV), the highly specific molluscum-like umbilicated skin lesions, and the classic red diffusing pigment in the room-temperature mold culture make this the only possible diagnostic conclusion. Following severe induction therapy with IV Amphotericin B to save his life, the preferred, mandatory maintenance drug to prevent relapse is oral Itraconazole.

Part XI: List of References & Clinical Guidelines

Bennett, J. E., Dolin, R., & Blaser, M. J. (2019). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (9th ed.). Elsevier. (Sections on Dimorphic Fungi and Blastomycosis).
Kasper, D. L., Fauci, A. S., Hauser, S. L., Longo, D. L., Jameson, J. L., & Loscalzo, J. (2018). Harrison's Principles of Internal Medicine (20th ed.). McGraw-Hill Education.
Centers for Disease Control and Prevention (CDC). (2021). Fungal Diseases: Blastomycosis. National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).
World Health Organization (WHO). (2017). Guidelines for the Diagnosis and Management of Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy. (Protocols for Talaromycosis management).
Limper, A. H., Knox, K. S., Sarosi, G. A., et al. (2011). An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients. American Journal of Respiratory and Critical Care Medicine.